HRMY Stock Analysis: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$37.26
1.26 (3.50%)
▲
5d:
+9.17%
30d:
+20.54%
90d:
+33.26%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 1.8% growth. Moderate conviction.
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 1.8% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$42.94
13.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $37.26, which is considered extended relative to its 30-day fair value range of $31.80 to $35.41. The stock's valuation (Forward PE: 6.2) is in line with its historical norms (5.9). At these levels, the market is pricing in 1.8% annual earnings growth.
Technical Outlook: Technically, HRMY is in a uptrend. The price is approaching resistance at $37.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: HRMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.91 (+20.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HRMY is in a uptrend. The price is approaching resistance at $37.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: HRMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.91 (+20.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$31.80 -
$35.41
Company Quality Score
65/100
(BUY)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
71.9%
Protect Your Profits
HRMY is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.2% above its trading range)
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 20.5% below Wall St target ($44.91)
- BULLISH: Expecting earnings turnaround to 1.8% growth with 16.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$31.80 -
$35.41
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$4.00
(10.7%)
Support & Resistance Levels
Support Level
$33.07
Resistance Level
$37.40
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.19
Wall Street Target
$44.91
(+20.5%)
Revenue Growth (YoY)
16.6%
Earnings Growth (YoY)
-29.5%
Profit Margin
16.2%
Valuation Premium vs History
+1.8% premium
PE vs Historical
6.2 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.8%
(market-implied from PE analysis)
1-Year Target
$37.93
(+2%)
2-Year Target
$38.61
(+4%)
3-Year Target
$39.31
(+6%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
PE COMPRESSION
$37.47
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 33.8%)
$314.27
(+743%)
Base:
(SPY PE: 6.2, Growth: 33.8%)
$89.31
(+140%)
Bear:
(PE: 5.3, Growth: 33.8%)
$75.92
(+104%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 14.52 | Current EPS (TTM): $2.48
Bull Case
$79.20
(+113%)
Analyst growth 100.0%, PE expands to 16.0
Base Case
$72.00
(+93%)
Market implied 100.0%, PE stable at 14.5
Bear Case
$24.48
(-34%)
Severe decline -20.0%, PE contracts to 12.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 3:47 PM ET
Data refreshes hourly during market hours. Next update: 4:47 PM
Data refreshes hourly during market hours. Next update: 4:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Sandip Kapadia
SELL
3746 shares
2026-01-26
Sandip Kapadia
SELL
20961 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
